Boston Scientific Reports (ADVENT) Study Results of FARAPULSE Pulsed Field Ablation System for Atrial Fibrillation
Shots:
- The company highlighted the 12mos. results from the (ADVENT) clinical trial evaluating efficacy & safety of FARAPULSE Pulsed Field Ablation (PFA) System vs SoC ablation (either radiofrequency or cryoablation) in 607 patients with AF
- The primary efficacy and safety EPs i.e., the single-procedure, off-drug treatment success was 73.3% vs 71.3% through 12mos., low AEs rate of 2.1% vs 1.5%. FARAPULSE PFA system was non-inferior to SoC therapies in the study's secondary safety EPs with less post-ablation narrowing of the pulmonary veins at 3mos. (0.9% vs 12%)
- Additionally, shorter ablation times and less variability with the FARAPULSE PFA System were seen. The results were presented at ESC Congress 2023 & published in the NEJM while the system received CE Mark in 2021
Ref: PRNewswire | Image: Boston Scientific
Related News:- Boston Scientific’s POLARx Cryoablation System Receives the US FDA’s Approval for Paroxysmal Atrial Fibrillation
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
